HDEC

Greenberg Traurig's Jaret L. Davis, Fred E. Karlinsky, and Jéan E. Wilson Recognized in Florida Trend's Florida 500

Retrieved on: 
Wednesday, November 1, 2023
Insurance, American College, Orlando Utilities Commission, City & State, Living Legend, Hartsfield–Jackson Atlanta International Airport, Supreme Court of Florida, Life, Orientation, HDEC, Wilson, Orlando International Airport, Organization, Davis, Law, Information technology, HQ2, University college, Growth, City, Politics, City National Bank of Florida, Florida Trend, Executive Committee, Holocaust Documentation & Education Center, Emerge America, Poverty, Advisory Council, Florida State University College of Law, City National Bank, Negotiation, Amazon, Orange, State government, Clothing, Airline, Greenberg Traurig, Central Florida

MIAMI, Nov. 1, 2023 /PRNewswire-PRWeb/ -- Greenberg Traurig, P.A. Shareholders Jaret L. Davis, Fred E. Karlinsky, and Jéan E. Wilson are recognized in Florida Trend's sixth-annual "Florida 500" issue, which highlights the "most influential business leaders" in over a dozen categories statewide.

Key Points: 
  • Shareholders Jaret L. Davis, Fred E. Karlinsky, and Jéan E. Wilson are recognized in Florida Trend's sixth-annual "Florida 500" issue, which highlights the "most influential business leaders" in over a dozen categories statewide.
  • Shareholders Jaret L. Davis , Fred E. Karlinsky , and Jéan E. Wilson are recognized in Florida Trend's sixth-annual "Florida 500" issue, which highlights the "most influential business leaders" in over a dozen categories statewide.
  • Davis, Karlinsky, and Wilson are among a select group of attorneys featured in the Law section.
  • "Jaret, Fred, and Jéan exemplify this commitment with their dedication to providing excellent client service and giving back to their communities.

Official Launch of Carbon-Neutrality Pilot Project in the China-EU (Taicang) Green and Digital Innovation Cooperation Zone

Retrieved on: 
Wednesday, August 9, 2023
Carbon, Sustainability, EDF, Ministry of Industry and Information Technology, CCTC, Information technology, Launch, CBS, User experience, Forum for European–Australian Science and Technology Cooperation, Korea Institute for International Economic Policy, Government, Digital, National Green Building Standard, Ministry of Ecology and Environment, Policy, ABB, Public sector, Huadong, Conference, Private sector, China-EU Institute for Clean and Renewable Energy, Ministry, Climate change, HDEC, United Nations, MEE, Orangi Pilot Project, Yangtze Delta, MIIT, Renewable energy, Ecology, Environment, Research, Dassault Group

BEIJING, Aug. 9, 2023 /PRNewswire/ -- On August 8th 2023, the Launch Meeting of Carbon-Neutrality Pilot Project in China-EU (Taicang) Green Digital and Innovation Cooperation Zone was held in Beijing, China.

Key Points: 
  • BEIJING, Aug. 9, 2023 /PRNewswire/ -- On August 8th 2023, the Launch Meeting of Carbon-Neutrality Pilot Project in China-EU (Taicang) Green Digital and Innovation Cooperation Zone was held in Beijing, China.
  • The core of China-EU (Taicang) Pilot Project is a "Digital Zero-Carbon Industrial Park", located in Taicang City, Jiangsu Province in the Yangtze River Delta region of China, adjacent to Shanghai.
  • 150,000, setting the goal of carbon neutral by 2028 with a whole-area traceable carbon footprint based on digital system.
  • Currently, the Secretariat of China Green Sustainable Development Association (CGSDA) is soliciting pilot projects and partners for the year 2024, which is open for global application.

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
Monday, August 7, 2023
Protalix BioTherapeutics, Medsafe, European Medicines Agency, Tax, MD, Patient, European, Fabry disease, BLA, NYSE, Calendar, Gout, Half-life, Pharmacokinetics, Research, EMA, Russell, FIH, Growth, FDA, PEGylation, Biologics license application, Safety, Civil service commission, Health, Baylor University Medical Center, Israel Innovation Authority, FASN, Webcast, MAA, HDEC, European Commission, KOL, Clinical trial, EDT, Marketing, ERT, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry, Drug, Life insurance, Online shopping, EU, Fabry, Chiesi Farmaceutici

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

The Global Antipsychotic Drugs Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsight

Retrieved on: 
Thursday, February 2, 2023
Pharmacy, Personality disorder, Pfizer, PTSD, Schizoaffective disorder, Safety, Sun Pharma, Lundbeck, Ethics, Cariprazine, Statistics, Anxiety, Alvogen, Bristol Myers Squibb, HDEC, Mental disorder, Bipolar I disorder, Disorder, Depression, Post-traumatic stress disorder, Food, Hallucination, DSM-IV codes, Zydus Lifesciences, Prevalence, USFDA, US Foods, LAS, Mental health, GSK, Laboratory, Government, MDMA, Thought, Addiction, USP, Schizophrenia, Sale, Bipolar disorder, Research, Agonist, Silvio Pettirossi International Airport, COVID-19, Bayer, GSK plc, Cardinal Health, World Health Organization, Drug development, Mania, WHO, Viatris, Conduct disorder, AbbVie, Delusion, Pharmaceutical industry, Medsafe

LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.

Key Points: 
  • LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global antipsychotic drugs market during the forecast period.
  • Furthermore, increased awareness resulted in increased adoption of these drugs in key countries, significantly increasing antipsychotic drugs market growth in key countries.
  • However, the high cost of drug development and launch, addiction caused by antipsychotic drugs, and the stringent regulatory approval process may stall the antipsychotic drugs market growth.

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

Retrieved on: 
Tuesday, September 27, 2022
Adult, Selective serotonin reuptake inhibitor, Therapy, PK, Safety, Amphetamine, Ethics, COVID-19, Infection, Brain, FDA, Addiction, Paroxetine, NEW, Norepinephrine, Senior, Intellectual property, MDMA, Private Securities Litigation Reform Act, HDEC, Hypertension, Stroke, Forward-looking statement, U.S. Securities and Exchange Commission, Public expenditure, Patient, Mental health, List of life sciences, CEO, Dopamine, Therapeutic index, Annual report, Nasdaq, Serotonin, Anxiety, Diagnosis, Cardiovascular disease, Pharmacology, Foundation for the National Institutes of Health, Research, Security (finance), GLOBE, Post-traumatic stress disorder, SEC, National Institute, Sertraline, PTSD, Failure, Depression, Pharmaceutical industry, Medsafe, Health

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

Key Points: 
  • Evidence shows that two-thirds of patients either do not respond or have only a partial response to these medications.
  • These modifications are designed to separate the entactogenic effects of MDMA from some of the known side effects, specifically its stimulant-associated effects.
  • Data on MDMA-assisted psychotherapy strongly suggests its potential for the treatment of PTSD, said Glenn Short, Senior Vice President, Early Development of atai Life Sciences.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Four Global Firms Shortlisted for Egypt’s $2 Billion Industrial Project

Retrieved on: 
Tuesday, August 23, 2022
Chemicals, Plastics, Commercial Building & Real Estate, Construction & Property, Manufacturing, FEED, Engineering, General authority, GDP, EPC, James McHugh Construction Co, Investment, USD, HDEC, Leonardo S.p.A., Intention, General Authority for Entertainment (Saudi Arabia), K.V.N. Naik S.P. Sanstha's Polytechnic, PDH, SAMSUNG, Record, Construction, Oil, S.A

The USD 2 billion project comprises a chemicals complex that will be built in the industrial zone of the General Authority for the Suez Canal Economic Zone (SCZONE) in Egypt.

Key Points: 
  • The USD 2 billion project comprises a chemicals complex that will be built in the industrial zone of the General Authority for the Suez Canal Economic Zone (SCZONE) in Egypt.
  • The firms were selected based on a thorough evaluation process which included strict criteria and a scoring system.
  • The project is in line with the Egypts plans to promote foreign direct investment, which has increased significantly in recent months.
  • Gulf states have pledged more than USD 22 billion to support the Egyptian economy, including billions in industrial projects.